Login to Your Account



Sarepta shares dive as FDA seeks more data on Duchenne's drug

By Michael Fitzhugh
Staff Writer

Monday, October 27, 2014
Sarepta Therapeutics Inc. shares (NASDAQ:SRPT) fell 32.5 percent Monday to $15.91 as it revealed FDA requests for new data on its late-stage Duchenne muscular dystrophy (DMD) candidate, eteplirsen, would delay until mid-2015 a planned new drug application (NDA) for the therapy.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription